VeClose trial 12-month outcomes of cyanoacrylate closure versus radiofrequency ablation for incompetent great saphenous veins

Size: px
Start display at page:

Download "VeClose trial 12-month outcomes of cyanoacrylate closure versus radiofrequency ablation for incompetent great saphenous veins"

Transcription

1 VeClose trial 12-month outcomes of cyanoacrylate closure versus radiofrequency ablation for incompetent great saphenous veins Nick Morrison, MD, a Kathleen Gibson, MD, b Michael Vasquez, MD, c Robert Weiss, MD, d Daniel Cher, MD, e Monte Madsen, RVT, RPhS, f and Andrew Jones, MD, g Scottsdale, Ariz; Bellevue, Wash; Buffalo, NY; Hunt Valley, Md; Palo Alto and Santa Rosa, Calif; and Bend, Ore ABSTRACT Objective: Endovenous cyanoacrylate closure (CAC) is a new U.S. Food and Drug Administration-approved therapy for treatment of clinically symptomatic venous reflux in saphenous veins. The device is indicated for the permanent closure of lower extremity superficial truncal veins, such as the great saphenous vein (GSV). Early results from a randomized trial of CAC have been reported previously. Herein we report 1-year outcomes. Methods: There were 222 subjects with symptomatic GSV incompetence randomly assigned to receive either CAC (n ¼ 108) or radiofrequency ablation (RFA; n ¼ 114). After the month 3 visit, subjects could receive adjunctive therapies aimed at treating visible varicosities and incompetent tributaries. Vein closure was assessed at day 3 and months 1, 3, 6, and 12 using duplex ultrasound. Additional study visit assessments included the Venous Clinical Severity Score; Clinical, Etiology, Anatomy, and Pathophysiology classification; EuroQol-5 Dimension; and Aberdeen Varicose Vein Questionnaire. Both time to closure and time to first reopening of the target vein were evaluated using survival curve analysis. Adverse events were evaluated at each visit. Results: Of 222 enrolled and randomized subjects, a 12-month follow-up was obtained for 192 (95 CAC and 97 RFA; total follow-up rate, 192/222 [86.5%]). By month 1, 100% of CAC subjects and 87% of RFA subjects demonstrated complete occlusion of the target vein. By month 12, the complete occlusion rate was nearly identical in both groups (97.2% in the CAC group and 97.0% in the RFA group). Twelve-month freedom from recanalization was similar in the CAC and RFA groups, although there was a trend toward greater freedom from recanalization in the CAC group (P ¼.08). Symptoms and quality of life improved equally in both groups. Most adverse events were mild to moderate and not related to the device or procedure. Conclusions: In patients with incompetent GSVs, treatment with both CAC and RFA results in high occlusion rates. Time to complete occlusion was faster with CAC, and freedom from reopening was higher after CAC. Quality of life scores improved equally with both therapies. (J Vasc Surg: Venous and Lym Dis 2017;5: ) Treatment of chronic venous disorders in the United States has shifted substantially in the past decade from surgical to endovenous treatment. Proven endovenous therapies comprise those that are heat based, including radiofrequency ablation (RFA) and endovenous laser ablation (EVLA). Both have gained widespread adoption and been shown to have high target vein closure rates with good safety profiles. 1 RFA is a segmental treatment process, whereas EVLA is a continuous process requiring the practitioner to gradually retract the laser fiber at a specified rate. Both modalities require the administration of tumescent anesthesia (TA) by multiple injections to infuse a diluted lidocaine and saline mixture into the perivenous space. TA protects the surrounding tissues and provides hypoesthesia when the thermal energy is From the Morrison Vein Institute, Scottsdale a ; Lake Washington Vascular, Bellevue b ; the Venous Institute of Buffalo, Buffalo c ; MD Laser Skin & Vein, Hunt Valley d ; Wild Iris Consulting LLC, Palo Alto e ; Medtronic, Santa Rosa f ; and the Inovia Vein Specialty Center, Bend. g The work was funded by Sapheon Inc. Sapheon was directly involved in the study design, collection, conduct, analysis, and interpretation of the data with the research investigators. Sapheon has since been acquired by Covidien, which was then acquired by Medtronic. Medtronic provided biostatistical and publication coordination support. Clinical Trial registration: NCT Author conflict of interest: N.M. has been paid a consulting fee by Medtronic, received financial support as an investigator, and is on Medtronic s speakers bureau; he has received an educational grant from mediusa and is on their speakers bureau. K.G. is on the scientific advisory board of Medtronic; receives research support from Medtronic, AngioDynamics, and BTG; and is a consultant for BTG. D.C. is a consultant to Medtronic, helping with writing and statistical analysis. M.V. is on the Medtronic speakers bureau. M.M. was an employee of Sapheon Inc and is currently employed by Medtronic. Presented as a podium presentation at the 2015 European Venous Forum, St. Petersburg, Russia, July 2-4, Correspondence: Nick Morrison, MD, 6301 S McClintock Dr, Ste 115, Tempe, AZ ( nickmorrison2002@yahoo.com). The editors and reviewers of this article have no relevant financial relationships to disclose per the Journal policy that requires reviewers to decline review of any manuscript for which they may have a conflict of interest X Copyright Ó 2017 The Authors. Published by Elsevier Inc. on behalf of the Society for Vascular Surgery. This is an open access article under the CC BY-NC-ND license (

2 322 Morrison et al Journal of Vascular Surgery: Venous and Lymphatic Disorders May 2017 delivered. Postprocedural pain and bruising are two of themostfrequentproblemsassociatedwiththermal therapies. 2,3 Because RFA had previously been shown to be superior to EVLA with respect to postoperative ecchymosis and pain, 4,5 it was selected as the control intervention for this study. Endovenous delivery of cyanoacrylate (cyanoacrylate closure [CAC]) has become available in the United States, Europe, and elsewhere (VenaSeal; Sapheon, Morrisville, NC). Early evidence from two clinical studies supports the safety and effectiveness of CAC for treatment of great saphenous vein (GSV) reflux, including a single-center 3-year study 6-8 and a multicenter, single-arm 3-year study. 9 Previously, we reported 3-month outcomes of the VenaSeal Sapheon Closure System Pivotal Study (VeClose), a randomized trial of CAC vs RFA. 10 We present herein 12-month VeClose results, focusing on time to complete closure, durability of closure, and symptom scores and quality of life measurements. METHODS Study design. A detailed description of the VeClose trial design, eligibility criteria, and outcomes through month 3 has been previously reported. 10 The VeClose trial is a multicenter, prospective, randomized controlled trial conducted under investigational device exemption from the Food and Drug Administration at 10 study centers in the United States. All investigators were experienced with endovenous treatments and highly experienced RFA users, with backgrounds in general surgery, vascular surgery, emergency medicine, and general medicine. In total, investigators have performed >17,000 RFA procedures and >20,000 laser procedures. All sites obtained central Institutional Review Board approval before enrollment, and all participants provided written informed consent. Patients eligible for inclusion in the trial were adults with symptomatic venous reflux and varicosities (Clinical, Etiology, Anatomy, and Pathophysiology [CEAP] clinical classification of symptomatic C2-C4b) and incompetence of the GSV, with reflux time of $0.5 second assessed in the standing position with duplex ultrasound. Key exclusion criteria were hemodynamically significant reflux of the small saphenous vein or anterior accessory GSV, prior treatment of the target GSV, symptomatic peripheral arterial disease, history of deep venous thrombosis or pulmonary embolism, and aneurysm of the target GSV >12 mm in diameter. The study s objective was to compare the safety and efficacy of CAC vs RFA in patients demonstrating GSV reflux. A Data and Safety Monitoring Board was used to monitor adverse events. Assessments. Before treatment, investigators performed a detailed vascular history and targeted physical examination and completed both CEAP and Venous Clinical Severity Score (VCSS) assessments. 11 Duplex ARTICLE HIGHLIGHTS d Type of Research: Multicenter randomized controlled trial d Take Home Message: At 1 year, cyanoacrylate-based chemical ablation had similar efficacy to radiofrequency ablation thermal ablation in terms of occlusion, durability, and relief from symptoms. d Recommendation: The authors recommend that there is little difference in efficacy between cyanoacrylate treatment and radiofrequency ablation for treatment of symptomatic saphenous reflux. ultrasound of both legs was then performed. Subjects completed the EuroQol-5 Dimension (EQ-5D) quality of life survey 12 and the Aberdeen Varicose Vein Questionnaire (AVVQ). 13 Randomization. Subjects were randomized (1:1) to either CAC (VenaSeal) or RFA (ClosureFast; both now manufactured by Medtronic, Plymouth, Minn). Randomization was stratified by study site and used random block sizes of four or six; assignments were obtained through an automated telephone service connected to a passwordprotected randomization table. Roll-in (training) cases (first 2 cases performed by each site, total of 20 subjects) were treated with CAC and analyzed separately. Devices and procedures. CAC was performed as previously described. 10 Briefly, the target vein was accessed, and a 7F introducer sheath coupled with a 5F delivery catheter was advanced 5 cm caudal to the saphenofemoral junction. With proximal GSV compression using the ultrasound probe, two 0.1-mL aliquots of cyanoacrylate were delivered 1 cm apart with additional hand compression at the treated segment for 3 minutes. Subsequent 0.1-mL aliquots were delivered at 3-cm intervals along the target treatment area, and compression with the ultrasound probe and free hand was performed for 30 seconds at each treated segment. Additional aliquots of 0.1 ml of adhesive were delivered in dilated areas. After the entire length of the vein was treated, the sheath and delivery catheter were removed, and compression was applied to the entry site. A small self-adhesive bandage was applied at the access site. RFA of the target vein was performed using the ClosureFast catheter according to the manufacturer s instructions for use. Perivenous TA was used with RFA but not for CAC. Both groups used postprocedure compression stockings for 3 days continuously and 4 additional days during waking hours. Postoperative study visits. Subjects returned to the investigational center at day 3 and months 1, 3, 6, and 12. Study follow-up will continue to year 3. At follow-up visits, investigators completed VCSS and CEAP scores,

3 Journal of Vascular Surgery: Venous and Lymphatic Disorders Morrison et al 323 Volume 5, Number 3 and subjects completed the AVVQ and EQ-5D. In addition, Doppler ultrasound of the treated vein was performed by vascular technologists and interpreted by the investigator. The analysis reported herein uses ultrasound interpretations performed by site investigators at months 1, 3, 6, and 12. (Note that a vascular ultrasound core laboratory [VasCore, Boston, Mass] interpreted ultrasound results for the study s primary end point at month 3, with no knowledge of the sites findings at the time of the readings, and core laboratory adjudications agreed 100% with investigator readings.) Ipsilateral adjunctive target vein treatments were disallowed until after the month 3 visit to avoid confounding the study s primary end point at month 3 but were allowed thereafter. End points and statistical methods. The study s previously reported primary end point was complete closure of the target GSV at month 3. Closure was defined as Doppler ultrasound examination (including color flow, compression, and pulsed Doppler) showing closure along the entire treated target vein segment with no discrete segments of patency exceeding 5 cm. Recanalization was defined as openings along the treated segment exceeding 5 cm in length as detected by duplex ultrasound. The likelihood of closure or recanalization was evaluated in several ways. First, time to closure of the target vein was calculated for each subject as the number of days from treatment to first observation of vein closure. Time to recanalization was calculated as the number of days from treatment to first instance of recanalization after the month 1 assessment (because total vein occlusion in RFA may take several weeks, minor [residual microlumen] openings before month 1 in the RFA group were not counted as recanalization). Survival curves were compared using Kaplan- Meier analysis. Differences in the proportion of subjects with complete closure of the target vein at month 12 were assessed using a noninferiority approach with confidence limits calculated using the method of Miettinen and Nurminen. 14 The study s noninferiority margin for the primary end point at month 3 was 10%. The same noninferiority margin was used for the 12-month assessment. If noninferiority was demonstrated, superiority was tested using identical methods. Bootstrapping methods were used to calculate the distribution of the difference in long-term survival rates. Changes from baseline in VCSS, AVVQ, and EQ-5D were compared between groups using repeated-measures analysis of variance. Changes in CEAP category were compared using a Wilcoxon test. Adverse event rates were compared using Fisher exact test. All analyses were performed using R. 15 RESULTS Subject characteristics and disposition. Between March and September 2013, 242 subjects meeting eligibility criteria were enrolled and treated. Twenty subjects Table I. Demographic characteristics of VeClose trial subjects Characteristics CAC (n ¼ 108) RFA (n ¼ 114) Female 83 (77) 93 (82) Nonwhite 6 (6) 8 (7) Age, years 49.0 (27-71) 51 (26-70) Body mass index 27.0 ( ) 27.0 ( ) Primary symptoms Pain 33 (31) 24 (21) Aching 32 (30) 39 (34) Itching 2 (2) 5 (4) Burning 5 (5) 3 (3) Sensitivity d d Heaviness 14 (13) 16 (14) Swelling 17 (16) 18 (16) Other 4 (4) 7 (6) GSV diameter, mm Mid GSV 4.9 (1.7-9) 5.1 (2.4-11) Proximal GSV 6.3 (3-12) 6.6 (2.8-12) CEAP classification C2 61 (57) 64 (56) C3 32 (30) 36 (32) C4a 13 (12) 12 (11) C4b 2 (2) 2 (2) VCSS 5.5 (2.6) 5.6 (2.6) AVVQ 18.9 (9.0) 19.4 (9.9) EQ-5D TTO (0.113) (0.116) AVVQ, Aberdeen Varicose Vein Questionnaire; CAC, cyanoacrylate closure; CEAP, Clinical, Etiologic, Anatomic, and Pathophysiologic; EQ-5D, EuroQoL-5 Dimension; GSV, great saphenous vein; RFA, radiofrequency ablation; TTO, time tradeoff; VCCS, Venous Clinical Severity Score. Categorical variables are presented as number (%). Continuous variables are presented as mean (standard deviation) or median (range). (two at each site, which on the basis of experience from previous clinical trials 6,9 was established as the number of cases necessary for initial device familiarity) were roll-in cases treated with CAC, which have been reported separately. 16 Of the subsequent 222 subjects, 108 were assigned to CAC and 114 to RFA. Consistent with subjects from other superficial venous reflux clinical trials, most subjects in this study were women (79%); most (87%) subjects were in the CEAP clinical classification 2 and 3 groups; and baseline characteristics were similar between treatment groups (Table I). Twelve months into the study, 198 subjects (89%) were still participating in the study (192 of whom had a month 12 visit), and 23 (10%) had withdrawn from the study (Fig 1). After month 3, approximately 41% of subjects in both groups underwent one or more adjunctive treatments of the ipsilateral leg. Time to permanent closure. The raw proportion of subjects with complete closure of the target vein was similar at month 12 (92/95 [96.8%] in the CAC group;

4 324 Morrison et al Journal of Vascular Surgery: Venous and Lymphatic Disorders May 2017 Fig 1. Consolidated Standards of Reporting Trials (CONSORT) flow diagram for subjects involved in the VeClose trial. The patients progress through the VeClose trial is indicated in the diagram, including final N values for each study group. CAC, Cyanoacrylate closure; ND, not defined; RFA, radiofrequency ablation. 93/97 [95.9%] in the RFA group). Using Kaplan-Meier analysis, the number of days to initial closure of the target vein was lower in the CAC group than in the RFA group (Fig 2; P ¼.0123). By month 1, 100% of CAC subjects and 87% of RFA subjects demonstrated complete occlusion of the target vein. By the month 3 visit, the occlusionrateintherfagroupwas94%.bymonth12, the complete occlusion rate was nearly identical in both groups (97.2% in the CAC group and 97.0% in the RFA group). Time to recanalization. The likelihood of recanalization was higher in the RFA group than in the CAC group (Fig 3). By month 3, there were three recanalizations in the CAC group and nine in the RFA group. Recanalization-free survival at month 12 was 97% for the CAC group vs 90.7% for the RFA group (P ¼.08 for superiority, P <.0001 for noninferiority). Subgroup analysis for comparisons of 12-month recanalization-free survival rates was limited by the small number of failures in the CAC group. Regarding adjunctive treatments for target vein closure, one CAC subject had an open vein at month 3 and underwent both phlebectomy and sclerotherapy soon after the month 3 visit. However, examination at months 6 and 12 showed target vein patency. The subject underwent a second session of adjunctive procedures, and closure was documented 367 days after the index procedure. Another CAC subject had persistent opening despite adjunctive treatment, and the third subject had patency at the month 12 visit despite receiving adjunctive treatments before the month 12 visit. In the RFA group, there were five subjects with no closure of the target vein at month 3. Adjunctive treatments in those subjects included phlebectomy and sclerotherapy, and target vein closure occurred in three of the five RFA subjects. Symptom scores and quality of life. During the course of the 12-month follow-up, disease severity as measured by VCSS and impact on quality of life as measured by AVVQ (Fig 4) decreased rapidly and equally in both groups

5 Journal of Vascular Surgery: Venous and Lymphatic Disorders Morrison et al 325 Volume 5, Number 3 Fig 2. Days to complete occlusion. Shown are the days to complete occlusion of the target vein for the cyanoacrylate closure (CAC; solid line) and radiofrequency ablation (RFA; dotted line) treatment groups. Number at risk is presented along the x-axis: top line, CAC; bottom line, RFA. (P ¼.5694 and P ¼.5536, respectively). Similarly, overall quality of life as measured by EQ-5D (Fig 5) increased by a small and similar amount across groups (P ¼.1645). Adverse events. As previously reported, 10 adverse events in the first 3 months were mild (including phlebitis, paresthesia in the treatment zone, stocking irritation, access site infection, and superficial thrombophlebitis) and occurred at a similar rate between groups. Between months 3 and 12 of follow-up, one subject (originally treated with CAC) had chronic phlebitis in the index leg attributed to the procedure. There were 37 other adverse events reported between month 3 and month 12. These were either phlebitis of nontarget regions or miscellaneous events unrelated to the venous vascular system (Table II). The majority of the adverse events reported were not related to the device or the procedure (eg, pregnancy, pneumonia, Fig 3. Time to recanalization. Shown is the time to recanalization of the target vein for the cyanoacrylate closure (CAC; solid line) and radiofrequency ablation (RFA; dotted line) treatment groups. Number at risk is presented along the x-axis: top line, CAC; bottom line, RFA.

6 326 Morrison et al Journal of Vascular Surgery: Venous and Lymphatic Disorders May 2017 Fig 4. Change in Venous Clinical Severity Score (VCSS) and Aberdeen Varicose Vein Questionnaire (AVVQ) score. Changes in VCSS (top) and AVVQ score (bottom) are shown by time for the cyanoacrylate closure (CAC; solid line) and radiofrequency ablation (RFA; dotted line) treatment groups. Number at risk is presented at each time point. SE, Standard error. and thyroid cancer), and those adverse events that were inflammatory in nature (eg, phlebitis, tenderness in index leg, cellulitis) were seen at similar rates in both groups (four patients in each group). All of the phlebitis cases were mild. Of the events that were considered related to the device, all resolved and none were considered severe. No thrombus extensions were reported in the CAC group, but two were identified in the RFA group, both of which resolved without sequelae. DISCUSSION In a previous publication of the current trial, 10 we demonstrated CAC to be a safe and effective treatment of GSV reflux, with similar safety and effectiveness at 3 months. However, longer term data with CAC are valuable in establishing its efficacy and long-term benefit to patients, especially in comparison to standard treatments such as RFA. This trial confirms CAC to be safe and effective during a 12-month period, with persistent improvements in benefits to the patient as shown in

7 Journal of Vascular Surgery: Venous and Lymphatic Disorders Morrison et al 327 Volume 5, Number 3 Fig 5. Change in EuroQol-5 Dimension (EQ-5D). Subjects in the VeClose trial completed the EQ-5D quality of life survey, which measures problems with mobility, self-care, and usual activities. Solid line, Cyanoacrylate closure (CAC); dotted line, radiofrequency ablation (RFA). Number at risk is presented at each time point. SE, Standard error; TTO, time tradeoff. quality of life surveys. Twelve-month occlusion rates were high in both arms of the study (>97%), and the study successfully showed noninferiority of CAC compared with RFA at month 12 (P ¼.0015). Time to complete occlusion of the target vein was lower with CAC than with RFA, and freedom from recanalization with CAC was noninferior (P <.0001) and trends toward superiority (P ¼.08) compared with that with RFA. It is known, however, that recanalization after thermal ablation does not necessarily portend recurrent symptoms, 17 and we did not observe any symptomatic differences at month 12. Compared with RFA, potential advantages of CAC include the lack of necessity for TA, which experience tells us is often uncomfortable for patients, even though in this particular group of patients, pain scores during the procedure were similar (and low) in both groups, as reported previously. 10 This lack of a difference and low scores reflects the experience of the investigators in minimizing the pain associated with delivery of TA and the minimal pain associated with CAC as well as the difficulty in showing significant differences when most patients are at the same end of the pain numeric rating scale (range of 0-10). A much larger cohort would need to be studied to identify a statistical trend in procedural pain. Another potential advantage of CAC is that additional capital equipment, such as an RFA laser generator or tumescent pump, is unnecessary. Although both treatment groups in this study were required to wear compression stockings after the procedure to have similar recovery protocols, previous CAC trials 6,9 did not require the use of postprocedure compression for subjects treated with CAC. Three subjects treated with CAC had incomplete vein closure at some point during follow-up. Veins of two CAC subjects were open at month 12 and one was open by month 3. Possible failure mechanisms for CAC include inadequate dosing for the diameter of the target vein, junctions with refluxing tributaries or perforators, and complex anatomy with multiple junctions along the target vein. In contrast, 19 subjects treated with RFA had open target veins observed during follow-up. Possible failure mechanisms for RFA include inadequate delivery of energy to the target vein, large diameter vein or aneurysmal segments, refluxing tributaries or perforators, and complex anatomy with multiple junctions along the target vein. Twelve-month closure rates were high and nearly identical in both groups. For subjects demonstrating incomplete closure who later demonstrated complete closure, it is possible that adjunctive treatment such as phlebectomy or foam sclerotherapy aided in obtaining closure. In the CAC group, two of the three subjects had persistent opening at month 12 despite adjunctive procedures. Whether adjunctive treatments helped RFA subjects obtain closure is challenging to determine with data from the current study. In clinical practice, adjunctive procedures such as concomitant microphlebectomy and sclerotherapy are common, 18 and further study would be necessary to determine whether

8 328 Morrison et al Journal of Vascular Surgery: Venous and Lymphatic Disorders May 2017 Table II. Adverse events between 3 and 12 months in the VeClose trial Treatment Adverse event description Related to device Related to procedure Severity Days to adverse event CAC Stomach pains Not related Not related Mild 113 CAC Pain after sclerotherapy Not related Not related Mild 105 CAC Seroma Not related Not related Mild 182 CAC Low back pain Not related Not related Mild 288 CAC Foot pain Not related Not related Mild 184 CAC Sinus pressure Not related Not related Mild 288 CAC Pregnancy Not related Not related Mild 169 CAC Patient pregnant Not related Not related Mild 209 CAC Rash above upper lip Not related Not related Mild 163 CAC Erythema Not related Not related Mild 132 CAC Phlebitis Not related Not related Mild 105 CAC Phlebitis Not related Not related Mild 175 CAC Symptomatic venous stasis Not related Not related Mild 173 CAC Thrombosed veins after sclerotherapy Not related Not related Mild 176 CAC Tenderness over phlebectomy site Not related Not related Moderate 116 CAC Pneumonia Not related Not related Moderate 107 CAC Tenderness left leg Not related Not related Moderate 168 CAC Asthma Not related Not related Moderate 258 CAC Small bowel obstruction Not related Not related Severe 286 CAC Thyroid cancer Not related Not related Severe 232 CAC Pain in right medial thigh Not related Possibly related Moderate 221 CAC Chronic phlebitis Possibly related Definitely related Mild 92 RFA DVT nonindex leg Definitely related Definitely related Moderate 172 RFA EHIT Definitely related Definitely related Moderate 172 RFA Abdomen pain Not related Not related Mild 175 RFA Lower abdomen pain Not related Not related Mild 174 RFA Lower right-sided back pain Not related Not related Mild 269 RFA Cervical radicular pain Not related Not related Mild 277 RFA Hyperpigmentation on index (right) leg Not related Not related Mild 181 RFA Superficial phlebitis Not related Not related Mild 165 RFA Phlebitis Not related Not related Mild 209 RFA Cellulitis Not related Not related Moderate 340 RFA Left hip bone pain Not related Not related Moderate 166 RFA Non-ST-segment elevation MI Not related Not related Severe 308 RFA Left groin discomfort Possibly related Possibly related Mild 97 RFA Phlebitis Possibly related Possibly related Mild 106 CAC, Cyanoacrylate closure; DVT, deep venous thrombosis; EHIT, endovenous heat-induced thrombosis; MI, myocardial infarction; RFA, radiofrequencyablation. adjunctive treatments performed concomitantly with CAC or RFA can improve GSV closure rates in the long term. Our observation of high closure rates at month 3 (before the delivery of adjunctive treatments) suggests that such treatments may reasonably be delayed. The recanalization rate was greater after the RFA procedure than with the CAC procedure. However, as some subjects underwent additional adjunctive treatments, long-term occlusion rates were high in both groups. It is unknown if this was a result of the natural history of vein destruction with RFA compared with the immediate occlusion with CAC or if the adjunctive treatment somehow led to occlusion of more of the RFA-treated GSVs. It is believed that recanalization after RFA occurs because thrombi, a consistent byproduct of thermal ablation techniques, may commonly result in recanalization. However, successful thermal ablation is not dependent on thrombus formation; rather, it depends on vein wall destruction, and unless there has been adequate vein wall destruction, the vein will fail to occlude

9 Journal of Vascular Surgery: Venous and Lymphatic Disorders Morrison et al 329 Volume 5, Number 3 permanently. 19 With CAC, there is little or no venous thrombosis as the venous lumen is immediately occluded with bonding of the intima by the adhesive, and this may explain the lower recanalization rate with CAC. 9,10 As expected with occlusion of a refluxing GSV, improvements in symptom severity as measured by VCSS, AVVQ, and EQ-5D were similar and high in both groups. Phlebitis was defined broadly in our study and categorized as in the treatment zone or outside it to ensure complete reporting. The onset and details of adverse events have been previously reported. 10 These inflammatory adverse events were more common in the CAC cohort, but the difference was not statistically significant. One potential explanation includes a greater inflammatory effect of the cyanoacrylate implant (the material is designed to cause a nonspecific, mild inflammatory response in the vein to promote vein closure). Posttreatment inflammation was, in all cases, mild, self-limited, and easily treated with a short course of nonsteroidal anti-inflammatory drugs. No deep venous thrombosis or pulmonary embolism occurred in any of the subjects secondary to the target treatment per the investigators. There was one case of gastrocnemius vein thrombus in a subject treated with endovenous laser on a contralateral (nonstudy limb) small saphenous vein 5.5 months after the randomized RFA treatment. CAC does not require TA, and the treatment results in a rapid occlusion of the treated vein. The viscosity and rapid polymerization of the adhesive do not allow it to freely flow with the blood. Once it is injected, it becomes more static, thus minimizing the risk of embolization that might be seen with less viscous adhesives. Thrombus extensions at the saphenofemoral junction were observed in the prior CAC clinical trials and were similar in appearance to the endothermal heat-induced thromboses seen with the endothermal treatments. 20 These extensions were most prevalent in the initial feasibility study that was conducted with a different treatment protocol from that of the current study. 6 One of the purported advantages of nonthermal technologies is the elimination of paresthesias, especially below the knee. There were a total of six cases (three in the CAC group and three in the RFA group), and inquiry of the investigators who had these subjects in the study revealed that the paresthesia was secondary to wearing of the compression hose (determined by the fact that the compression hose were removed in response to the patient s complaints, and the paresthesia resolved in a matter of minutes). This data point was not well defined in the case report forms, and no additional information is available. Strengths of the study include its randomized design; its careful assessment of clinical outcomes, symptom scores, and ultrasound assessments at scheduled time points; and careful tracking of adjunctive procedures. All data were reviewed by external monitors and source verified. Agreement at the 3-month end points between investigator reads and core laboratory reads was high, suggesting that investigator reads at other time points were sufficiently accurate. Limitations of this trial include a modest dropout rate, with month 12 data unavailable for 13 of 108 (12.0%) subjects in the CAC group (9 withdrawn and 4 visits not done) and 19 of 114 (16.6%) subjects in the RFA group (8 withdrawn and 11 visits not done). Blinding, although potentially advantageous, was not feasible because RFA requires TA administration and CAC has characteristic findings on ultrasound. 10 However, the primary study outcome (anatomic closure) was easily judged with ultrasound and is objective. Ultrasound interpretations performed by study investigators could have introduced bias; however, the core laboratory had no knowledge of the sites findings at the time of the readings, and their findings agreed with those of the investigators (there was 100% agreement between investigator reads and core laboratory reads; k statistic was 1.0). To minimize confounding due to non-device-related postintervention factors, subjects in both groups were asked to use compression stockings after the index procedure for 7 days. This was done solely for the trial, but it was not done for two prior studies of CAC. 6,9 Whether compression stockings improve complete occlusion rates could be the subject of further study. CONCLUSIONS In this study, both CAC and RFA were associated with high rates of target vein occlusion at month 12. Both time to closure and recanalization rates were lower with CAC than with RFA. Improvements in generic and disease-specific quality of life scores were similar across both groups up to month 12; thus, the benefits of CAC appear to be as durable as those of RFA in the midterm. Follow-up of subjects will continue to year 3. AUTHOR CONTRIBUTIONS Conception and design: NM Analysis and interpretation: NM, KG, AJ, MV, RW, DC, MM Data collection: NM, KG, AJ, MV, RW, MM Writing the article: NM, KG, AJ, MV, RW, DC, MM Critical revision of the article: NM, KG, AJ, MV, RW, DC, MM Final approval of the article: NM, KG, AJ, MV, RW, DC, MM Statistical analysis: NM, DC, MM Obtained funding: NM Overall responsibility: NM REFERENCES 1. van den Bos R, Arends L, Kockaert M, Neumann M, Nijsten T. Endovenous therapies of lower extremity varicosities: a meta-analysis. J Vasc Surg 2009;49:230-9.

10 330 Almeida Journal of Vascular Surgery: Venous and Lymphatic Disorders May Anwar MA, Lane TR, Davies AH, Franklin IJ. Complications of radiofrequency ablation of varicose veins. Phlebology 2012;27(Suppl 1): Dexter D, Kabnick L, Berland T, Jacobowitz G, Lamparello P, Maldonado T, et al. Complications of endovenous lasers. Phlebology 2012;27(Suppl 1): Rasmussen LH, Lawaetz M, Bjoern L, Vennits B, Blemnigs A, Eklof B. Randomized clinical trial comparing endovenous laser ablation, radiofrequency ablation, foam sclerotherapy and surgical stripping for great saphenous varicose veins. Br J Surg 2011;98: Almeida JI, Kaufman J, Gockeritz O, Chopra P, Evans M, Hoheim D, et al. Radiofrequency endovenous ClosureFAST versus laser ablation for the treatment of great saphenous reflux: a multicenter, single-blinded, randomized study (RE- COVERY study). J Vasc Interv Radiol 2009;20: Almeida JI, Javier JJ, Mackay EG, Bautista C, Proebstle TM. First human use of cyanoacrylate adhesive for treatment of saphenous vein incompetence. J Vasc Surg Venous Lymphat Disord 2013;1: Almeida JI, Javier JJ, Mackay EG, Bautista C, Cher D, Proebstle T. Two-year follow-up of first human use of cyanoacrylate adhesive for treatment of saphenous vein incompetence. Phlebology 2015;30: Almeida JI, Javier JJ, Mackay EG, Bautista C, Cher D, Proebstle TM. Three-year follow-up of first human use of cyanoacrylate adhesive for treatment of saphenous vein incompetence. J Vasc Surg Venous Lymphat Disord 2015;3: Proebstle TM, Alm J, Dimitri S, Rasmussen L, Whiteley M, Lawson J, et al. The European multicenter cohort study on cyanoacrylate embolization of refluxing great saphenous veins. J Vasc Surg Venous Lymphat Disord 2015;3: Morrison N, Gibson K, McEnroe S, Goldman M, King T, Weiss R, et al. Randomized trial comparing cyanoacrylate embolization and radiofrequency ablation for incompetent great saphenous veins (VeClose). J Vasc Surg 2015;61: Vasquez MA, Munschauer CE. Venous Clinical Severity Score and quality-of-life assessment tools: application to vein practice. Phlebology 2008;23: EuroQol Group. EuroQolda new facility for the measurement of health-related quality of life. Health Policy 1990;16: Garratt AM, Macdonald LM, Ruta DA, Russell IT, Buckingham JK, Krukowski ZH. Towards measurement of outcome for patients with varicose veins. Qual Health Care 1993;2: Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med 1985;4: R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; Available at: Kolluri R, Gibson K, Cher D, Madsen M, Weiss R, Morrison N. Roll-in phase analysis of clinical study of cyanoacrylate closure for incompetent great saphenous veins. J Vasc Surg Venous Lymphat Disord 2016;4: Theivacumar NS, Dellagrammaticas D, Darwood RJ, Mavor AI, Gough MJ. Fate of the great saphenous vein following endovenous laser ablation: does re-canalisation mean recurrence? Eur J Vasc Endovasc Surg 2008;36: Welch HJ. Endovenous ablation of the great saphenous vein may avert phlebectomy for branch varicose veins. J Vasc Surg 2006;44: Puggioni A, Marks N, Hingorani A, Shiferson A, Alhalbouni S, Ascher E. The safety of radiofrequency ablation of the great saphenous vein in patients with previous venous thrombosis. J Vasc Surg 2009;49: Rhee SJ, Cantelmo NL, Conrad MF, Stoughton J. Factors influencing the incidence of endovenous heat-induced thrombosis (EHIT). Vasc Endovascular Surg 2013;47: Submitted Jul 15, 2016; accepted Dec 13, INVITED COMMENTARY Jose I. Almeida, MD, Miami, Fla Compared with standard surgery, endovenous thermal ablation has fewer complications, quicker recovery, and improved quality of life and cosmetic outcomes. However, endovenous thermal ablation requires tumescent anesthesia and carries a small risk of thermal-related complications, such as paresthesia, prolonged pain, and skin burn. The insertion of tumescent fluid can also be uncomfortable. Because of these drawbacks, interest in nonthermal alternatives has increased. Nonthermal alternatives require neither tumescent anesthesia nor the purchase of expensive thermal energy delivery systems. Cyanoacrylate closure (CAC), with a high-viscosity n-butyl cyanoacrylate, offers rapid polymerization and target vein fibrosis. A similar n-butyl cyanoacrylate (TRUFILL; DePuy Synthes, West Chester, Pa) is a safe, proven, liquid embolic system for treatment of arteriovenous malformations; >15,000 patients have been treated. Medical skin adhesives (Dermabond; Ethicon, Somerville, NJ) are composed of 2-octyl cyanoacrylate and behave differently. Early evidence from several feasibility studies supports the safety and effectiveness of this same proprietary high-viscosity n-butyl cyanoacrylate for treatment of great saphenous vein reflux; and the authors of this study previously reported 3-month outcomes of a randomized trial of CAC vs radiofrequency ablation (RFA). These 12-month VenaSeal Sapheon Closure System Pivotal Study (VeClose) results focus on time to complete closure, durability of closure, symptom scores, and quality of life measurements. Of 222 enrolled and randomized subjects, a 12-month follow-up was obtained for 95 CAC patients and 97 RFA patients (192/222 [86.5%]). By month 1, 100% of CAC subjects and 87% of RFA subjects demonstrated complete occlusion of the target vein. By month 12, the complete occlusion rate was nearly identical in both groups (97.2% in the CAC

Randomized trial comparing cyanoacrylate embolization and radiofrequency ablation for incompetent great saphenous vein

Randomized trial comparing cyanoacrylate embolization and radiofrequency ablation for incompetent great saphenous vein Randomized trial comparing cyanoacrylate embolization and radiofrequency ablation for incompetent great saphenous vein Raghu Kolluri, MD, Director Vascular Medicine OhioHealth Riverside Methodist Hospital

More information

VeClose trial Cyanoacylate closure vs. RF ablation 36-month results

VeClose trial Cyanoacylate closure vs. RF ablation 36-month results VeClose trial Cyanoacylate closure vs. RF ablation 36-month results LINC 2018, Leipzig 31 st Jan 2018 Tobias Hirsch, Halle, Germany www.gefaessmedizin-hirsch.de Disclosure Tobias Hirsch I have the following

More information

MOCA and GLUE: results and analyses of the RCTs

MOCA and GLUE: results and analyses of the RCTs MOCA and GLUE: results and analyses of the RCTs Faculty disclosure Research Grant Medtronic Educational Grant mediusa Speakers Bureau Medtronic Pierre Fabre mediusa Medical Director Morrison Vein/Training

More information

Kathleen Gibson, MD. Lake Washington Vascular Surgeons Bellevue, WA

Kathleen Gibson, MD. Lake Washington Vascular Surgeons Bellevue, WA Cyanoacrylate Closure of Incompetent Great, Small and Accessory Saphenous Veins without the use of Post-Procedure Compression: a Post-Market Evaluation of the VenaSeal System (WAVES trial): Three Month

More information

Thermal Techniques: Outcomes and Complications

Thermal Techniques: Outcomes and Complications Thermal Techniques: Outcomes and Complications Meet The Experts: Thermal and Non-Thermal Ablation Techniques Joseph D. Raffetto MD VA Boston HCS, West Roxbury, MA, Harvard Medical School, Boston, MA; Brigham

More information

Management of Superficial Reflux: Which option, when? Kathleen Gibson, MD Lake Washington Vascular Surgeons Bellevue, WA

Management of Superficial Reflux: Which option, when? Kathleen Gibson, MD Lake Washington Vascular Surgeons Bellevue, WA Management of Superficial Reflux: Which option, when? Kathleen Gibson, MD Lake Washington Vascular Surgeons Bellevue, WA DISCLOSURES Kathleen Gibson, MD Consultant/Advisory Board: BTG, Medtronic Speakers

More information

Epidemiology: Prevalence

Epidemiology: Prevalence Epidemiology: Prevalence More than 30 million Americans suffer from varicose veins or a more serious form of venous disease called Chronic Venous Insufficiency (CVI). 1 Of the over 30 million Americans

More information

Criteria For Medicare Members. Kaiser Foundation Health Plan of Washington

Criteria For Medicare Members. Kaiser Foundation Health Plan of Washington Clinical Review Criteria Treatment of Varicose Veins Radiofrequency Catheter Closure Sclerotherapy Surgical Stripping Trivex System for Outpatient Varicose Vein Surgery VenaSeal Closure System VNUS Closure

More information

Clinical case. Symptomatic anterior accessory great saphenous vein (AAGSV) reflux

Clinical case. Symptomatic anterior accessory great saphenous vein (AAGSV) reflux Clinical case Symptomatic anterior accessory great saphenous vein (AAGSV) reflux A 70 year-old female presents with symptomatic varicose veins on left leg for more than 10 years. She complains of heaviness,

More information

Endovenous Thermal vs. Endovenous Chemical Ablation What is the Best for the Patient

Endovenous Thermal vs. Endovenous Chemical Ablation What is the Best for the Patient Endovenous Thermal vs. Endovenous Chemical Ablation What is the Best for the Patient T. Noppeney, J. Noppeney Center for Vascular Diseases: Outpatient Dept. Obere Turnstrasse, Dept. for Vascular Surgery

More information

A treatment option for varicose veins. enefit" Targeted Endovenous Therapy. Formerly known as the VNUS Closure procedure E 3 COVIDIEN

A treatment option for varicose veins. enefit Targeted Endovenous Therapy. Formerly known as the VNUS Closure procedure E 3 COVIDIEN A treatment option for varicose veins. enefit" Targeted Endovenous Therapy Formerly known as the VNUS Closure procedure E 3 COVIDIEN THE VENOUS SYSTEM ANATOMY The venous system is made up of a network

More information

Kathleen Gibson, MD FACS Lake Washington Vascular Surgeons, Bellevue, WA, USA

Kathleen Gibson, MD FACS Lake Washington Vascular Surgeons, Bellevue, WA, USA Cyanoacrylate Closure of Incompetent Great, Small and Accessory Saphenous Veins without the use of Post-Procedure Compression: Post-Market Evaluation of the VenaSeal System (WAVES trial): 12 Month Data

More information

Conflict of Interest. None

Conflict of Interest. None Conflict of Interest None American Venous Forum Guidelines on Superficial Venous Disease TOP 10 GUIDELINES 10. We recommend using the CEAP classification to describe chronic venous disorders. (GRADE 1B)

More information

N.S. Theivacumar, R.J. Darwood, M.J. Gough*

N.S. Theivacumar, R.J. Darwood, M.J. Gough* Eur J Vasc Endovasc Surg (2009) 37, 477e481 Endovenous Laser Ablation (EVLA) of the Anterior Accessory Great Saphenous Vein (): Abolition of Sapheno-Femoral Reflux with Preservation of the Great Saphenous

More information

Additional Information S-55

Additional Information S-55 Additional Information S-55 Network providers are encouraged, but not required to participate in the on-line American Venous Forum Registry (AVR) - The First National Registry for the Treatment of Varicose

More information

FIND RELIEF FROM VARICOSE VEINS. VenaSeal Closure System

FIND RELIEF FROM VARICOSE VEINS. VenaSeal Closure System FIND RELIEF FROM VARICOSE VEINS VenaSeal Closure System UNDERSTAND Varicose veins may be a sign of something more severe venous reflux disease Your doctor can help you understand if you have this condition.

More information

Find From Varicose Veins. VenaSeal

Find From Varicose Veins. VenaSeal Find Relief From Varicose Veins VenaSeal Closure System Understand Varicose veins may be a sign of something more severe venous reflux disease. Your doctor can help you understand if you have this condition.

More information

Sadie Ahanchi, MD Sentara Vascular Specialists April 27,2018. Debate 1: Why Is Tumescent-Based Therapy The Gold Standard?

Sadie Ahanchi, MD Sentara Vascular Specialists April 27,2018. Debate 1: Why Is Tumescent-Based Therapy The Gold Standard? Sadie Ahanchi, MD Sentara Vascular Specialists April 27,2018 Debate 1: Why Is Tumescent-Based Therapy The Gold Standard? Tumescent based venous therapy: Fight! Introduction Tumescent anesthesia Administration

More information

Cyanoacrylate vs laser ablation. Turkish experience. A. Kursat Bozkurt MD University of Istanbul

Cyanoacrylate vs laser ablation. Turkish experience. A. Kursat Bozkurt MD University of Istanbul Cyanoacrylate vs laser ablation. Turkish experience A. Kursat Bozkurt MD University of Istanbul Disclosure Speaker name: A. Kursat Bozkurt I have the following potential conflicts of interest to report:

More information

Chronic Venous Insufficiency Compression and Beyond

Chronic Venous Insufficiency Compression and Beyond Disclosure of Conflict of Interest Chronic Venous Insufficiency Compression and Beyond Shawn Amyot, MD, CCFP Fellow of the Canadian Society of Phlebology Ottawa Vein Centre I do not have relevant financial

More information

Closurefast radiofrequency ablation for the treatment of GSV: Technique and outcome results

Closurefast radiofrequency ablation for the treatment of GSV: Technique and outcome results Closurefast radiofrequency ablation for the treatment of GSV: Technique and outcome results Stephen Black Consultant Vascular Surgeon Clinical Lead for Venous and Lymphoedema Surgery Guy s and St Thomas

More information

Perforators: When to Treat and How Best to Do It? Eric Hager, MD September 10, 2015

Perforators: When to Treat and How Best to Do It? Eric Hager, MD September 10, 2015 Perforators: When to Treat and How Best to Do It? Eric Hager, MD September 10, 2015 Anatomy of Perforating veins Cadaveric studies 1 have shown >60 vein perforating veins from superficial to deep Normal

More information

FIND RELIEF FROM VARICOSE VEINS. VenaSeal Sapheon Closure System

FIND RELIEF FROM VARICOSE VEINS. VenaSeal Sapheon Closure System FIND RELIEF FROM VARICOSE VEINS VenaSeal Sapheon Closure System UNDERSTAND Varicose veins may be a sign of something more severe. Your doctor can help you understand if you have this condition. may cause

More information

Why Tumescent-Free Therapy Will Replace RF and Laser

Why Tumescent-Free Therapy Will Replace RF and Laser C SCOTT MCENROE Medical Director Vein Center of Virginia Sentara Medical Group April 27, 2018 Why Tumescent-Free Therapy Will Replace RF and Laser History of Venous Surgery 1950 s GSV/SSV stripping became

More information

Medicare C/D Medical Coverage Policy

Medicare C/D Medical Coverage Policy Varicose Vein Treatment Medicare C/D Medical Coverage Policy Origination Date: June 1, 1993 Review Date: February 15, 2017 Next Review: February, 2019 DESCRIPTION OF PROCEDURE OR SERVICE Varicose veins

More information

Vein Disease Treatment

Vein Disease Treatment MP9241 Covered Service: Yes when meets criteria below Prior Authorization Required: Yes as indicated in 2.0, 3.0, 4.0 and 5.0 Additional Information: None Prevea360 Health Plan Medical Policy: Vein disease

More information

Srovnání 2 typů radiálních laserových vláken (1-ringových a 2-ringových) v nitrožilní léčbě křečových žil pomocí laseru o vlnové délce 1470 nm

Srovnání 2 typů radiálních laserových vláken (1-ringových a 2-ringových) v nitrožilní léčbě křečových žil pomocí laseru o vlnové délce 1470 nm Srovnání 2 typů radiálních laserových vláken (1-ringových a 2-ringových) v nitrožilní léčbě křečových žil pomocí laseru o vlnové délce 1470 nm Robert Vlachovský, Robert Staffa, Ernest Biroš II. chirurgická

More information

OHTAC Recommendation. Endovascular Laser Treatment for Varicose Veins. Presented to the Ontario Health Technology Advisory Committee in November 2009

OHTAC Recommendation. Endovascular Laser Treatment for Varicose Veins. Presented to the Ontario Health Technology Advisory Committee in November 2009 OHTAC Recommendation Endovascular Laser Treatment for Varicose Veins Presented to the Ontario Health Technology Advisory Committee in November 2009 April 2010 Issue Background The Ontario Health Technology

More information

Influence of Warfarin on the Success of Endovenous Laser Ablation (EVLA) of the Great Saphenous Vein (GSV)

Influence of Warfarin on the Success of Endovenous Laser Ablation (EVLA) of the Great Saphenous Vein (GSV) Eur J Vasc Endovasc Surg (2009) 38, 506e510 Influence of Warfarin on the Success of Endovenous Laser Ablation (EVLA) of the Great Saphenous Vein (GSV) N.S. Theivacumar, M.J. Gough* Leeds Vascular Institute,

More information

Surgery or combined endolaser ablation and sclerotherapy for varicose veins, a new trend in a developing country (Iraq); a cohort study

Surgery or combined endolaser ablation and sclerotherapy for varicose veins, a new trend in a developing country (Iraq); a cohort study Surgery or combined endolaser ablation and sclerotherapy for varicose veins, a new trend in a developing country (Iraq); a cohort study Bashar Hanna Azar (1) Ashur Yohanna Izac Oraha (2) Emad Abdulrahman

More information

Patient assessment and strategy making for endovenous treatment

Patient assessment and strategy making for endovenous treatment Patient assessment and strategy making for endovenous treatment Raghu Kolluri, MD Director Vascular Medicine OhioHealth Riverside Methodist Hospital Columbus, OH Disclosures Current Medtronic Consultant/

More information

Endo-Thermal Heat Induced Thrombosis (E-HIT)

Endo-Thermal Heat Induced Thrombosis (E-HIT) Endo-Thermal Heat Induced Thrombosis (E-HIT) Michael Ombrellino MD FACS The Cardiovascular Care Group Clinical Associate Professor of Surgery Rutgers School of Medicine Objectives: What is E-HIT? How do

More information

Non-Saphenous Vein Treatments. Jessica Ochs PA-C Albert Vein Institute Colorado Springs and Lone Tree, CO

Non-Saphenous Vein Treatments. Jessica Ochs PA-C Albert Vein Institute Colorado Springs and Lone Tree, CO Non-Saphenous Vein Treatments Jessica Ochs PA-C Albert Vein Institute Colorado Springs and Lone Tree, CO I have no financial disclosures Types of Veins Treated Perforator Veins Tributary Veins Varicose

More information

RECOGNITION AND ENDOVASCULAR TREATMENT OF CHRONIC VENOUS INSUFFICIENCY

RECOGNITION AND ENDOVASCULAR TREATMENT OF CHRONIC VENOUS INSUFFICIENCY RECOGNITION AND ENDOVASCULAR TREATMENT OF CHRONIC VENOUS INSUFFICIENCY Paul Kramer, MD, FACC, FSCAI Liberty Cardiovascular Specialists Liberty Regional Heart and Vascular Center DISCLOSURES NONE Venous

More information

Long-term follow up for different varicose vein therapies: is surgery still. the best?

Long-term follow up for different varicose vein therapies: is surgery still. the best? Long-term follow up for different varicose vein therapies: is surgery still the best? Mr Roshan BOOTUN [BSc, MBBS, MRCS] Clinical Research Fellow in Vascular Surgery Professor Alun H. DAVIES [BA, BM BCh,

More information

New Technologies in Superficial Vein Treatment

New Technologies in Superficial Vein Treatment New Technologies in Superficial Vein Treatment Ariel D. Soffer, MD, FACC Associate Clinical Professor Florida International University Medical School Ariel Soffer, MD, FACC Bio Fellow of the American College

More information

Varicose veins that develop due to chronic venous insufficiency

Varicose veins that develop due to chronic venous insufficiency Diagn Interv Radiol 2012; 18:594 598 Turkish Society of Radiology 2012 INTERVENTIONAL RADIOLOGY ORIGINAL ARTICLE Early clinical improvement in chronic venous insufficiency symptoms after laser ablation

More information

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of cyanoacrylate glue occlusion for varicose veins Varicose veins in the legs are

More information

Laser and Radiofrequency Ablation Study (LARA study): A Randomised Study Comparing Radiofrequency Ablation and Endovenous Laser Ablation (810 nm)

Laser and Radiofrequency Ablation Study (LARA study): A Randomised Study Comparing Radiofrequency Ablation and Endovenous Laser Ablation (810 nm) Eur J Vasc Endovasc Surg (2010) 40, 246e253 Laser and Radiofrequency Ablation Study (LARA study): A Randomised Study Comparing Radiofrequency Ablation and Endovenous Laser Ablation (810 nm) S.D. Goode,

More information

How varicose veins occur

How varicose veins occur Varicose veins are a very common problem, generally appearing as twisting, bulging rope-like cords on the legs, anywhere from groin to ankle. Spider veins are smaller, flatter, red or purple veins closer

More information

chapter 4 Randomized clinical trial of steam ablation (LAST trial) for great saphenous varicose veins

chapter 4 Randomized clinical trial of steam ablation (LAST trial) for great saphenous varicose veins Randomized clinical trial of EVSA versus EVLA 1 http://hdl.handle.net/1765/111020 chapter 4 Randomized clinical trial of endovenous Randomized clinical laser trial ablation of endovenous versus laser ablation

More information

Current Management of Varicose Veins

Current Management of Varicose Veins Current Management of Varicose Veins Michael J. Heidenreich, MD St. Joseph Mercy Hospital Ann Arbor, MI March 23, 2013 Nothing to disclose History Prevalence Anatomy Risk factors Clinical manifestations

More information

Management of Side Branches and Perforating Veins

Management of Side Branches and Perforating Veins Management of Side Branches and Perforating Veins T. Noppeney Center for Vascular Diseases: Outpatient Dept. Obere Turnstrasse, Dept. for Vascular Surgery Martha-Maria Hospital (Academic Teaching Hospital

More information

Treatment of Venous ulcers utilizing n-butyl Cyanoacrylate (Super Glue)

Treatment of Venous ulcers utilizing n-butyl Cyanoacrylate (Super Glue) Treatment of Venous ulcers utilizing n-butyl Cyanoacrylate (Super Glue) Awais Siddique MD Endovascular Radiologist AZH WAVE CENTERS Milwaukee WI Venous disease Etiology Are the result of Venous valvular

More information

Are there differences in guidelines for management of CVD between Europe and the US? Bo Eklöf, MD, PhD Lund University Sweden

Are there differences in guidelines for management of CVD between Europe and the US? Bo Eklöf, MD, PhD Lund University Sweden Are there differences in guidelines for management of CVD between Europe and the US? Bo Eklöf, MD, PhD Lund University Sweden Disclosures No disclosures Five sources for comparison SVS/AVF US guidelines

More information

Single-visit endovenous laser treatment and tributary procedures for symptomatic great saphenous varicose veins

Single-visit endovenous laser treatment and tributary procedures for symptomatic great saphenous varicose veins VASCULAR Ann R Coll Surg Engl 2014; 96: 279 283 doi 10.1308/003588414X13814021679474 Single-visit endovenous laser treatment and tributary procedures for symptomatic great saphenous varicose veins LS Alder,

More information

Venous Disease and Leg Ulcers. Edward G Mackay MD St. Petersburg, FL NCVH 2015 Orlando, FL

Venous Disease and Leg Ulcers. Edward G Mackay MD St. Petersburg, FL NCVH 2015 Orlando, FL Venous Disease and Leg Ulcers Edward G Mackay MD St. Petersburg, FL NCVH 2015 Orlando, FL Disclosures Stocks Endoshape Sapheon Medical Advisory Board BTG, Boston Scientific Venous Leg Ulcer Most common

More information

Endothermal Ablation for Venous Insufficiency. Dr. S. Kundu Medical Director The Vein Institute of Toronto

Endothermal Ablation for Venous Insufficiency. Dr. S. Kundu Medical Director The Vein Institute of Toronto Endothermal Ablation for Venous Insufficiency Dr. S. Kundu Medical Director The Vein Institute of Toronto Objective: remove the GSV from the circulation 1. Surgical - HL & stripping 2. Chemical sclerotherapy

More information

TREATMENT OPTIONS FOR CHRONIC VENOUS INSUFFICIENCY

TREATMENT OPTIONS FOR CHRONIC VENOUS INSUFFICIENCY TREATMENT OPTIONS FOR CHRONIC VENOUS INSUFFICIENCY TL LUK Consultant Vascular Surgeon Sarawak General Hospital HKL Vascular Conference 19/06/2013 PREVALENCE OF LOWER LIMB VENOUS DISEASE Affects half of

More information

Endovenous laser obliteration for the treatment of primary varicose veins Vuylsteke M, Van den Bussche D, Audenaert E A, Lissens P

Endovenous laser obliteration for the treatment of primary varicose veins Vuylsteke M, Van den Bussche D, Audenaert E A, Lissens P Endovenous laser obliteration for the treatment of primary varicose veins Vuylsteke M, Van den Bussche D, Audenaert E A, Lissens P Record Status This is a critical abstract of an economic evaluation that

More information

The occlusion rate and patterns of saphenous vein after radiofrequency ablation

The occlusion rate and patterns of saphenous vein after radiofrequency ablation J Korean Surg Soc 2013;84:107-113 http://dx.doi.org/10.4174/jkss.2013.84.2.107 ORIGINAL ARTICLE JKSS Journal of the Korean Surgical Society pissn 2233-7903 ㆍ eissn 2093-0488 The occlusion rate and patterns

More information

SURGICAL AND ABLATIVE PROCEDURES FOR VENOUS INSUFFICIENCY AND VARICOSE VEINS

SURGICAL AND ABLATIVE PROCEDURES FOR VENOUS INSUFFICIENCY AND VARICOSE VEINS UnitedHealthcare Commercial Medical Policy SURGICAL AND ABLATIVE PROCEDURES FOR VENOUS INSUFFICIENCY AND VARICOSE VEINS Policy Number: 2018T0447V Effective Date: March 1, 2018 Table of Contents Page INSTRUCTIONS

More information

CEAP <.0001) < % (98.0%) 245 (95.7%) (74.1%) ( P

CEAP <.0001) < % (98.0%) 245 (95.7%) (74.1%) ( P Three-year European follow-up of endovenous radiofrequency-powered segmental thermal ablation of the great saphenous vein with or without treatment of calf varicosities Thomas M. Proebstle, MD, PhD, a

More information

Treatment of Varicose Veins/Venous Insufficiency

Treatment of Varicose Veins/Venous Insufficiency Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided

More information

Endovenous Laser Ablation (EVLA) to Treat Recurrent Varicose Veins

Endovenous Laser Ablation (EVLA) to Treat Recurrent Varicose Veins Eur J Vasc Endovasc Surg (2011) 41, 691e696 Endovenous Laser Ablation (EVLA) to Treat Recurrent Varicose Veins N.S. Theivacumar, M.J. Gough* Leeds Vascular Institute, The General Infirmary at Leeds, Great

More information

Al-Metwaly Ragab Ibrahim Vascular Surgery; Al-Azhar faculty of Medicine- New Damietta, Egypt.

Al-Metwaly Ragab Ibrahim Vascular Surgery; Al-Azhar faculty of Medicine- New Damietta, Egypt. International Journal of Basic and applied Sciences. Vol. 4. No. 4. 2015. Pp. 259-264 Copyright by CRDEEP Journals. All Rights Reserved Full Length Research Paper Comparative Study between Endovenous Laser

More information

Understanding venous disease and treatment options for your patients. Christopher Wulff, MD

Understanding venous disease and treatment options for your patients. Christopher Wulff, MD Understanding venous disease and treatment options for your patients Christopher Wulff, MD Understanding Chronic venous insufficiency (CVI) Important Statistics About CVI Affects all age groups 1 Is ten

More information

Chronic Venous Insufficiency

Chronic Venous Insufficiency Chronic Venous Insufficiency None Disclosures Lesley Enfinger, MSN,NP-C Chronic Venous Insufficiency Over 24 Million Americans affected by Chronic Venous Insufficiency (CVI) 10 x More Americans suffer

More information

Table VIII. OS versus EVLA. New article

Table VIII. OS versus EVLA. New article Table VIII. OS EVLA. New article Operative procedure OS EVLA for for GSV or SSV incompetence Reference Abstracts corresponding to references can be found using the listing RCTs by alphabetical order or

More information

Complications of endovenous lasers

Complications of endovenous lasers Review article Complications of endovenous lasers D Dexter, L Kabnick, T Berland, G Jacobowitz, P Lamparello, T Maldonado, F Mussa, C Rockman, M Sadek, L E Giammaria and M Adelman New York University Medical

More information

PROVIDER POLICIES & PROCEDURES

PROVIDER POLICIES & PROCEDURES PROVIDER POLICIES & PROCEDURES TREATMENT OF VARICOSE VEINS OF THE LOWER EXTREMITIES STAB PHLEBECTOMY AND SCLEROTHERAPY TREATMENT The primary purpose of this document is to assist providers enrolled in

More information

Treatment of Varicose Veins/Venous Insufficiency

Treatment of Varicose Veins/Venous Insufficiency MEDICAL POLICY 7.01.519 Treatment of Varicose Veins/Venous Insufficiency BCBSA Ref. Policy: 7.01.124 Effective Date: March 1, 2017 Last Revised: Jan. 23, 2018 Replaces: 7.01.55, 7.01.76, 7.01.515, and

More information

Research Article Effects of Two Current Great Saphenous Vein Thermal Ablation Methods on Visual Analog Scale and Quality of Life

Research Article Effects of Two Current Great Saphenous Vein Thermal Ablation Methods on Visual Analog Scale and Quality of Life Hindawi BioMed Research International Volume 2017, Article ID 8532149, 6 pages https://doi.org/10.1155/2017/8532149 Research Article Effects of Two Current Great Saphenous Vein Thermal Ablation Methods

More information

Disclosures. What is a Specialty Vein Clinic? Prevalence of Venous Disease. Management of Venous Disease: an evidence based approach.

Disclosures. What is a Specialty Vein Clinic? Prevalence of Venous Disease. Management of Venous Disease: an evidence based approach. Management of Venous Disease: an evidence based approach Disclosures Ed Boyle, MD Andrew Jones, MD Dr. Ed Boyle and Dr. Andrew Jones disclose Grants/research support: Medtronic, BTG International, Clearflow,

More information

Medical Policy. Description/Scope. Position Statement

Medical Policy. Description/Scope. Position Statement Subject: Document #: Publish Date: 12/27/2017 Status: Revised Last Review Date: 05/04/2017 Description/Scope This document addresses various modalities (listed below) for the treatment of valvular incompetence

More information

SURGICAL AND ABLATIVE PROCEDURES FOR VENOUS INSUFFICIENCY AND VARICOSE VEINS

SURGICAL AND ABLATIVE PROCEDURES FOR VENOUS INSUFFICIENCY AND VARICOSE VEINS UnitedHealthcare Commercial Medical Policy SURGICAL AND ABLATIVE PROCEDURES FOR VENOUS INSUFFICIENCY AND VARICOSE VEINS Policy Number: 2017T0447T Effective Date: July 1, 2017 Table of Contents Page INSTRUCTIONS

More information

Recurrent Varicose Veins We All See Them

Recurrent Varicose Veins We All See Them We All See Them November 4, 2017 Austin, TX Arlington Heights, IL No conflicts Terminology REVAS REcurrent Varices After Surgery PREVAIT PREsence of Varices After Interventional Treatment Recurrent varices

More information

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of endovenous mechanochemical ablation for varicose veins Varicose veins in the legs

More information

6/1/2017. Mechanico-Chemical Ablation MOCA? Disclaimer

6/1/2017. Mechanico-Chemical Ablation MOCA? Disclaimer Cox Health Venous Symposium June 2-3, 207 Mechanico-Chemical Ablation Non-thermal, Non-tumescent Venous Ablation Therapy ROBERT W. VORHIES, M.D., F.A.C.S. VASCULAR AND ENDOVASCULAR SURGERY ENDOVENOUS THERAPY

More information

Date: A. Venous Health History Form. Patient please complete questions Primary Care Physician:

Date: A. Venous Health History Form. Patient please complete questions Primary Care Physician: E S Insurance: 2 nd Insurance: Wait time: Date: A. Venous Health History Form Patient please complete questions 1-12 Patient Name: SSN#: Date of Birth: Primary Care Physician: What is the reason for your

More information

Patient Information. Venous Insufficiency and Varicose Veins

Patient Information. Venous Insufficiency and Varicose Veins Patient Information Venous Insufficiency and Varicose Veins What is a Varicose Vein? Gitter Vein Institute-revised 3/8/2016 2 Frequently Asked Questions What is the difference between varicose and spider

More information

LINC, Christine Teichert, MD University Medicine of Rostock, Dept. of diagnostic and interventional radiology, Germany

LINC, Christine Teichert, MD University Medicine of Rostock, Dept. of diagnostic and interventional radiology, Germany Comparison of the efficacy, safety, the primary and secondary technical success of the endovenous nonthermal, tumescensless mechanochemical ablation of varicose veins with the subjective outcome using

More information

N.S. Theivacumar, R. Darwood, M.J. Gough* KEYWORDS Neovascularisation; Recurrence; Varicose vein; EVLA; Sapheno-femoral junction; GSV

N.S. Theivacumar, R. Darwood, M.J. Gough* KEYWORDS Neovascularisation; Recurrence; Varicose vein; EVLA; Sapheno-femoral junction; GSV Eur J Vasc Endovasc Surg (2009) 38, 203e207 Neovascularisation and Recurrence 2 Years After Varicose Vein Treatment for Sapheno-Femoral and Great Saphenous Vein Reflux: A Comparison of Surgery and Endovenous

More information

MedStar Health, Inc. POLICY AND PROCEDURE MANUAL Policy Number: MP.066.MH Last Review Date: 11/08/2018 Effective Date: 01/01/2019

MedStar Health, Inc. POLICY AND PROCEDURE MANUAL Policy Number: MP.066.MH Last Review Date: 11/08/2018 Effective Date: 01/01/2019 MedStar Health, Inc. POLICY AND PROCEDURE MANUAL This policy applies to the following lines of business: MedStar Employee (Select) MedStar CareFirst PPO MedStar Health considers the treatment of Varicose

More information

Priorities Forum Statement

Priorities Forum Statement Priorities Forum Statement Number 9 Subject Varicose Vein Surgery Date of decision September 2014 Date refreshed March 2017 Date of review September 2018 Relevant OPCS codes: L841-46, L848-49, L851-53,

More information

VIRTUS: Trial Design and Primary Endpoint Results

VIRTUS: Trial Design and Primary Endpoint Results VIRTUS: Trial Design and Primary Endpoint Results Mahmood K. Razavi, MD St. Joseph Cardiac and Vascular Center Orange, CA, USA IMPORTANT INFORMATION: These materials are intended to describe common clinical

More information

The Use of Adjunctive Venography and Endovascular Manoeuvres In The Treatment of Saphenous Vein Insufficiency. A Prospective, Multi-centre Study

The Use of Adjunctive Venography and Endovascular Manoeuvres In The Treatment of Saphenous Vein Insufficiency. A Prospective, Multi-centre Study The Use of Adjunctive Venography and Endovascular Manoeuvres In The Treatment of Saphenous Vein Insufficiency A Prospective, Multi-centre Study Ramon L. Varcoe, MBBS, MS, FRACS, PhD Associate Professor

More information

Comparison of Monopolar and Segmental Radiofrequency Ablation in the Treatment of Lower Limb Chronic Venous Insufficiency

Comparison of Monopolar and Segmental Radiofrequency Ablation in the Treatment of Lower Limb Chronic Venous Insufficiency ARC Journal of Surgery Volume 4, Issue 3, 218, PP 5-1 ISSN 2455-572X DOI: http://dx.doi.org/1.2431/2455-572x.432 www.arcjournals.org Comparison of Monopolar and Segmental Radiofrequency Ablation in the

More information

Randomized Clinical Trial Comparing Endovenous Laser Ablation and. Stripping of the Great Saphenous Vein with Clinical and Duplex

Randomized Clinical Trial Comparing Endovenous Laser Ablation and. Stripping of the Great Saphenous Vein with Clinical and Duplex Randomized Clinical Trial Comparing Endovenous Laser Ablation and Stripping of the Great Saphenous Vein with Clinical and Duplex outcome after 5 years Authors: Rasmussen LH, Lawaetz M, Bjoern L, Blemings

More information

Thermal Ablation 101: Basics of RF and Laser

Thermal Ablation 101: Basics of RF and Laser 1:48-2:00 Now 11 min flying Thermal ablation indications, contraindications, results, complications (30 min) Thermal Ablation 101: Basics of RF and Laser Nick Morrison, MD, FACPh, FACS, RPhS President,

More information

UNDERSTANDING VEIN DISEASE. UC EN - For use in the U.S. only

UNDERSTANDING VEIN DISEASE. UC EN - For use in the U.S. only UNDERSTANDING VEIN DISEASE UC201706537 EN - For use in the U.S. only Do you need to sit down during your work day because your legs ache and/or swell? Do you miss out on doing the activities you love because

More information

Le varici recidive Recurrent varices: how to manage them?

Le varici recidive Recurrent varices: how to manage them? Le varici recidive Recurrent varices: how to manage them? Marianne De Maeseneer MD PhD, Vascular Surgeon Department of Dermatology, Rotterdam, Netherlands & Faculty of Medicine and Health Sciences University

More information

SURGICAL AND ABLATIVE PROCEDURES FOR VENOUS INSUFFICIENCY AND VARICOSE VEINS

SURGICAL AND ABLATIVE PROCEDURES FOR VENOUS INSUFFICIENCY AND VARICOSE VEINS UnitedHealthcare Oxford Clinical Policy SURGICAL AND ABLATIVE PROCEDURES FOR VENOUS INSUFFICIENCY AND VARICOSE VEINS Policy Number: OUTPATIENT 013.32 T2 Effective Date: February 1, 2018 Table of Contents

More information

Table XI. Reference Abstracts corresponding to references can be found using the listing RCTs by alphabetical order or RCTs by topic.

Table XI. Reference Abstracts corresponding to references can be found using the listing RCTs by alphabetical order or RCTs by topic. Table XI. Operative procedure EVLA with different wavelengths HL+ EVLA EVLA without HL EVLA GSV ablation AK GSV ablation AK+BK Reference Abstracts corresponding to references can be found using the listing

More information

RADIOFREQUENCY ABLATION. Drs PIRET V, BERGERON P MEET CANNES 2009

RADIOFREQUENCY ABLATION. Drs PIRET V, BERGERON P MEET CANNES 2009 RADIOFREQUENCY ABLATION Drs PIRET V, BERGERON P MEET CANNES 2009 Superficial Venous Disease: EPIDEMIOLOGY Touch 75% of french population at different degrees (45.10 6 ) 25% needs medical care (11.10 6

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Varicose Veins Page 1 of 37 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Varicose Veins Professional Institutional Original Effective Date: January 1, 2004 Original

More information

What might bring a new wavelength for endovenous laser? Lowell S. Kabnick, MD, RPhS, FACS

What might bring a new wavelength for endovenous laser? Lowell S. Kabnick, MD, RPhS, FACS What might bring a new wavelength for endovenous laser? Lowell S. Kabnick, MD, RPhS, FACS Division of Vascular and Endovascular Surgery Faculty disclosure Lowell Kabnick, MD NOTHING TO DISCLOSE IS 1950nm

More information

VENASEAL CLOSURE SYSTEM

VENASEAL CLOSURE SYSTEM Sponsored by Medtronic Fall 2015 VENASEAL CLOSURE SYSTEM Is Cyanoacrylate Safe for Peripheral Venous Applications? By Nick Morrison, MD, FACPh, FACS, RPhS Clinical EvidenceBehind the VenaSeal Closure System

More information

The role of ultrasound duplex in endovenous procedures

The role of ultrasound duplex in endovenous procedures The role of ultrasound duplex in endovenous procedures Neophytos A. Zambas MD, PhD Vascular Surgeon Polyclinic Ygia, Limassol, Cyprus ΚΕΑΕΧ ΚΥΠΡΙΑΚΗ ΕΤΑΙΡΕΙΑ ΑΓΓΕΙΑΚΗΣ ΚΑΙ ΕΝΔΑΓΓΕΙΑΚΗΣ ΧΕΙΡΟΥΡΓΙΚΗΣ Pre

More information

POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY

POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY Original Issue Date (Created): July 12, 2003 Most Recent Review Date (Revised): May 20, 2014 Effective Date: October 1, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT

More information

Randomized clinical trial of VNUS ClosureFAST TM radiofrequency ablation versus laser for varicose veins

Randomized clinical trial of VNUS ClosureFAST TM radiofrequency ablation versus laser for varicose veins Randomized clinical trial Randomized clinical trial of VNUS ClosureFAST TM radiofrequency ablation versus laser for varicose veins A.C.Shepherd,M.S.Gohel,L.C.Brown,M.J.Metcalfe,M.HamishandA.H.Davies Imperial

More information

GENTLE ABLATION WITH RFITT TECHNOLOGY. For varicose vein treatment

GENTLE ABLATION WITH RFITT TECHNOLOGY. For varicose vein treatment GENTLE ABLATION WITH RFITT TECHNOLOGY For varicose vein treatment CELON RFITT METHOD For healthy and beautiful legs CELON has developed a leading bipolar radiofrequency ablation (RFA) system that can be

More information

Treatment of Varicose Veins/Venous Insufficiency. Description

Treatment of Varicose Veins/Venous Insufficiency. Description Page: 1 of 24 Last Review Status/Date: March 2015 Description A variety of treatment modalities are available to treat varicose veins/venous insufficiency, including surgical approaches, thermal ablation,

More information

Thrombosis of the Saphenous Vein Stump after Varicose Vein Surgery

Thrombosis of the Saphenous Vein Stump after Varicose Vein Surgery 2016 Annals of Vascular Diseases doi:10.300/avd.oa.16-000 Original Article Thrombosis of the Saphenous Vein Stump Varicose Vein Surgery Hiroto Rikimaru, MD, PhD We evaluated thrombus extension in the proximal

More information

Clinical/Duplex Evaluation of Varicose Veins: Who to Treat?

Clinical/Duplex Evaluation of Varicose Veins: Who to Treat? Clinical/Duplex Evaluation of Varicose Veins: Who to Treat? Sanjoy Kundu MD, FASA, FCIRSE, FSIR The Vein Institute of Toronto Scarborough Vascular Group Scarborough Vascular Ultrasound Scarborough Vascular

More information

Treatment of Varicose Veins

Treatment of Varicose Veins Treatment of Varicose Veins Policy Number: Original Effective Date: MM.06.016 04/15/2005 Line(s) of Business: Current Effective Date: PPO; HMO; QUEST Integration 09/28/2018 Section: Surgery Place(s) of

More information

Ramon R. J. P. van Eekeren, MD,a Doeke Boersma, MD,b Vincent Konijn, MD,a Jean Paul P. M. de Vries, MD, PhD,b Michel M. J. P. Reijnen, MP, PhD,a

Ramon R. J. P. van Eekeren, MD,a Doeke Boersma, MD,b Vincent Konijn, MD,a Jean Paul P. M. de Vries, MD, PhD,b Michel M. J. P. Reijnen, MP, PhD,a Postoperative pain and early quality of life after radiofrequency ablation and mechanochemical endovenous ablation of incompetent great saphenous veins Ramon R. J. P. van Eekeren, MD, a Doeke Boersma,

More information